TB (Tuberculosis) Preventive Therapy for HIV Patients With Access to HAART (Highly Active Antiretroviral Therapy)
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if implementing a policy of widespread INH
(Isoniazid) prophylaxis therapy in HIV-infected patients with access to antiretroviral
therapy reduces the incidence of active TB disease in the HIV clinic population.
Phase:
Phase 4
Details
Lead Sponsor:
Johns Hopkins University
Collaborators:
Bill and Melinda Gates Foundation Communicable Disease Program, Brazil Consortium to Respond Effectively to the AIDS/Tuberculosis Epidemic